^
CANCER:

Thymic Carcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Thymic Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thymic Carcinoma
GEM-CAP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
LV5FU2
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CaT
Sensitive
:
A2
KIT mutation
Thymic Carcinoma
sunitinib
Sensitive
:
A2
No biomarker
Thymic Carcinoma
VIP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
EP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
ADOC
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CAP + prednisone
Sensitive
:
A2
No biomarker
Thymic Carcinoma
CAP
Sensitive
:
A2
No biomarker
Thymic Carcinoma
carboplatin
Sensitive
:
A2
No biomarker
Thymic Carcinoma
paclitaxel
Sensitive
:
A2
No biomarker
Thymic Carcinoma
ifosfamide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
etoposide oral
Sensitive
:
A2
No biomarker
Thymic Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thymic Carcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Thymic Carcinoma
prednisone + octreotide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
octreotide
Sensitive
:
A2
No biomarker
Thymic Carcinoma
everolimus
Sensitive
:
A2
No biomarker
Thymic Carcinoma
pemetrexed
Sensitive
:
A2
EIF4EBP1 expression
Thymic Carcinoma
everolimus
Resistant
:
C3
HER-2 positive
Thymic Carcinoma
pyrotinib
Sensitive
:
C3
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive
:
C3
IGF1R expression
Thymic Carcinoma
everolimus
Resistant
:
C3
KIT exon 17 mutation
Thymic Carcinoma
avapritinib
Sensitive
:
C3
KIT D820Y
Thymic Carcinoma
sorafenib
Sensitive
:
C4
PD-L1 overexpression
Thymic Carcinoma
pembrolizumab
Sensitive
:
C4
PD-L1 overexpression
Thymic Carcinoma
pembrolizumab
Resistant
:
C4
EGFR exon 20 insertion
Thymic Carcinoma
anlotinib
Sensitive
:
C4
EGFR exon 19 deletion
Thymic Carcinoma
icotinib
Sensitive
:
C4
MSLN expression
Thymic Carcinoma
BAY 94-9343
Sensitive
:
D